ZNF133 Knockout cell line (A549)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

ZNF133 (zinc finger protein 133) encodes a zinc finger transcriptional regulator predicted to bind DNA in a sequence-specific manner and regulate RNA polymerase II-dependent transcription. It is predicted to function primarily in the nucleus and to negatively regulate transcription by RNA polymerase II. These properties suggest that ZNF133 may contribute to control of gene expression through interactions with specific regulatory DNA sequences.

A549 is a human lung cancer cell line established in 1972 from an explanted lung tumor of a 58-year-old male patient. The cells exhibit characteristics of alveolar type II pulmonary epithelial cells, including the ability to synthesize lecithin through the cytidine diphosphocholine pathway. A549 cells have been described as originating from lung adenocarcinoma and are widely used as a model for studying lung cancer biology, pulmonary epithelial function, drug responses, and respiratory-related research.

Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.